Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
VenatoRx
Biotech
Atai, Eli Lilly, Novartis & more—Chutes & Ladders
Atai announces CEO transition plans. Lilly's Alonzo Weems will retire after 27 years. Novartis China President set to lead all ex-US commercial work.
Max Bayer
,
Gabrielle Masson
May 17, 2024 8:30am
New year, new C-suite execs—Chutes & Ladders
Jan 6, 2023 9:30am
Lack of policy, investment stifling antibiotics pipeline
Apr 12, 2022 9:00am
Venatorx hits goal in antibiotic phase 3, clearing path to FDA
Mar 10, 2022 8:25am
AMR Centre picks up Medivir’s superbug-busting candidate
Oct 5, 2017 11:31am
VenatoRx raises $42M to fund antibiotic R&D
Jul 25, 2017 8:35am
